Lv73
3660 积分 2022-07-29 加入
Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies
20小时前
已完结
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases
4天前
已完结
Novel inhibitors of STAT3: an updated patent review (2022–present)
7天前
已完结
Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders
8天前
已完结
Discovery of TQ-3959 as a Potent and Orally Bioavailable BTK PROTAC Degrader Incorporating a Novel Benzisoxazole-Based CRBN Ligand for the Treatment of B-Cell Malignancies
13天前
已完结
Chemical Proteomics Identifies RBBP7 as a New E3 Ligase Supporting Targeted Protein Degradation
19天前
已完结
Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations
26天前
已完结
Novel Highly Potent c-Met Degraders against a Broad Range of Cancers
26天前
已完结
Discovery and structural optimization of potent epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M/C797S resistance mutation for lung cancer treatment
29天前
已完结
Discovery of a Novel EGFR PROTAC Degrader against C797S Resistance Mutation with Potent Antitumor Efficacy in NSCLC Treatment
29天前
已完结
皖公网安备34019202002308
